Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.61 |
| ▸ | CYP2E1 | P05181 | 6/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 6/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10583914 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL10928011 | 0.82 | NOS2 (0.65) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL10582367 | 0.78 | CYP1A2 (0.63) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL6483161 | 0.76 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL10541126 | 0.76 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL11685283 | 0.75 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL11687634 | 0.74 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL599673 | 0.74 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL10926513 | 0.74 | CYP1A2 (0.36) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 | |
| Water SCHEMBL4488115 | 0.73 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2E1CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0304732-A2 | Substituted thienoimidazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-01 | — | — | EP | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| EP-0304732-A2 | Substituted thienoimidazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-01 | — | — | EP | disclosed |
| EP-0201094-A2 | Thieno[2,3-d]imidazole derivatives and process for their preparation | Hafslund Nycomed Pharma Aktiengesellschaft (AT) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | CYP1A2 2281/4885CYP2C9 1120/4885CYP2E1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.